People Going Blind From GLP-1: Risks, Evidence and Protection Recent reports have raised concerns about potential links between GLP-1 medications and vision problems, prompting questions about whether people are going blind from GLP-1 treatments
This combination pairs BPC-157 (15-amino acid gastric pentadecapeptide) with TB-500 (43-amino acid Thymosin Beta-4 fragment) in a single formulation
Supplementing 2,000 to 4,000 IU daily is generally recommended
Endokrinologisches Kolloquium der Universittsklinik Lbeck, 25.3.1993
J Alzheimers Dis 2013;35:179-98.ArticlePubMed 22
Equity securities risk: Equity securities fluctuate in value and price in response to factors specific to the issuer of the security, such as management performance, financial condition, and market demand for the issuer's products or services, as well as factors unrelated to the fundamental condition of the issuer, including general market, economic, and political conditions